National Vaccine
Information Center

Your Health. Your Family. Your Choice.
Search Results

This is VAERS ID 1743066

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 10/15/2021

VAERS ID: 1743066
VAERS Form:2
Vaccin­ation / Manu­facturer Lot / Dose Site / Route

Administered by: Other      Purchased by: ??
Symptoms: Asthenia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? Yes
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? Yes
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Asthma; Dermatitis atopic; Eosinophilic granulomatosis with polyangiitis; Food allergy (allergy to honey, fruits, latex.); Latex allergy (allergy to honey, fruits, latex.)
Diagnostic Lab Data:
CDC 'Split Type': JPPFIZER INC202101206978

Write-up: Weakness; This is a spontaneous report from a contactable physician received via COVID-19. A 31-years-old male patient received first dose of BNT162b2 (COMIRNATY, Solution for injection, Lot Number: FF3622; Expiration Date: 30Nov2021), via intramuscular route, administered in left arm on 06Sep2021 at 15:00 (the day of vaccination, at the age of 31 years old) as dose 1, single for COVID-19 immunisation. Other medical history included eosinophilic granulomatosis with polyangiitis, asthma and dermatitis atopic from an unknown date. The patient had allergies to honey, fruits, latex. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medication within 2 weeks of vaccination included montelukast sodium, prednisolone acetate (PREDONINE), tacrolimus, hydrocortisone acetate (CORTRIL) all taken for an unspecified indication, start and stop date were not reported. On 06Sep2021 at 15:15 (15 minutes after vaccination), the patient experienced weakness. The outcome of the event was recovered on an unspecified date in 2021 with treatment including intravenous injection. The reporter stated the event results in emergency room/department or urgent care. Since the vaccination, the patient has not been tested for COVID-19. No follow-up attempts are needed. No further information is expected. Sender''s Comments: Based on the information currently available, a possible contributory role of the suspect vaccine BNT162B2 or comirnarty in triggering the onset of asthenia cannot be excluded.The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.

New Search

Link To This Search Result:

Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166